Bruno Vision Care has received the US Food and Drug Administration’s (FDA’s) approval for its Deseyne daily disposable contact lens (CL), designed to offer boosted hydration, comfort and clarity.  

Deseyne isn’t just another hydrogel CL; its delivery technology is setting a new standard in CL technology, said Eddie Catalfamo, CEO of Bruno Vision Care. “With our patented FusionTechnology proprietary manufacturing process and the novel vifilcon C material, we’re setting a new standard in vision health. The result is a lens that allows more people to wear contacts comfortably, provides existing wearers with greater hydration and clearer vision and makes fitting easier for eyecare professionals. It’s a true breakthrough for the industry and a game-changer for consumers.” 

The Deseyne lens integrates two patented innovations: vifilcon C, an enriched hydrogel lens material, and the FusionTechnology delivery system. This involves bioactive substances resembling tears and known as ‘lachryceuticals’ (consisting of hyaluronic acid with tamarind-seed polysaccharides), being embedded into the lens matrix during manufacturing. Their release is activated by body heat, blinking and eyelid pressure, delivering them to the anterior segment and guaranteeing their bioavailability during wear, improving hydration for natural, long-lasting comfort, Catalfamo said.  

Bruno Vision Care said the Deseyne lenses are expected to be available to US consumers in the fourth quarter of 2025.